CHD or CLX or PG

Key Takeaways

• Procter & Gamble offers the largest scale and strongest dividend track record, with 70 consecutive years of payout increases and a market capitalization exceeding $348 billion, but faces near-term cost headwinds from tariffs and commodities.
• Church & Dwight has delivered the strongest year-to-date price performance among the three, gaining approximately 17.7% in 2026, supported by consistent earnings beats and a diversified consumer portfolio anchored by the Arm & Hammer brand.
• Clorox remains the most deeply discounted of the group on a P/E basis, trading near 15x earnings with a dividend yield above 5%, but continues to work through ERP (Enterprise Resource Planning) system disruptions, lowered guidance, and slower-than-expected brand recoveries.
• All three stocks belong to the Consumer Staples sector and serve as defensive holdings, yet their recent trajectories have diverged significantly, with CHD showing relative momentum and CLX underperforming both peers and the broader market over the past year.
• Analyst consensus skews most favorably toward PG (Moderate Buy), followed by CHD (Hold/Buy), while CLX carries the most cautious Street sentiment (Reduce/Hold).

Introduction

Investors seeking exposure to the Consumer Staples sector often gravitate toward household names with durable demand, recognizable brand portfolios, and consistent cash-flow generation. CHD, CLX, and PG — Church & Dwight, Clorox, and Procter & Gamble — represent three distinct tiers within this space, ranging from a mid-cap specialty player to a global industry giant. This stock comparison examines how these three consumer packaged goods companies stack up in the current market environment, offering perspective for both income-oriented investors and those evaluating relative performance, valuation sensitivity, and operational momentum across the household and personal care landscape.

CHD Overview and Recent Performance

CHD, known for its flagship Arm & Hammer brand alongside OxiClean, Trojan, TheraBreath, Batiste, and Vitafusion, generates roughly 80% of its sales within the United States. With a market capitalization near $23.5 billion, the company occupies a mid-tier position in consumer staples — large enough to command meaningful shelf space yet more concentrated in its category exposure than its larger peers.

In recent weeks, CHD has traded around the $98–$99 range, near the midpoint of its 52-week span of $81.33 to $106.04. The stock's year-to-date gain of approximately 17.7% reflects steady upward momentum, aided by a first-quarter earnings report in which the company posted EPS (earnings per share) of $0.95, exceeding the consensus estimate of $0.93, alongside revenue of $1.47 billion that narrowly beat expectations. The company reaffirmed full-year 2026 EPS guidance of $3.71 to $3.81, providing a measure of visibility that markets have responded to positively. Institutional activity has been notably active, with several large asset managers increasing positions during recent quarters, while insider selling — totaling approximately $4.7 million over a recent 90-day period — has introduced a modest counterweight to bullish sentiment. Wells Fargo maintained an Overweight rating and raised its price target to $110 in recent weeks, contributing to an analyst consensus that leans constructive, with an average target near $103.47. With a beta of 0.47, CHD exhibits low volatility relative to the broader market.

CLX Overview and Recent Performance

CLX commands one of the most recognized brand portfolios in household products, including Clorox bleach and disinfecting wipes, Pine-Sol, Glad trash bags, Burt's Bees, Kingsford charcoal, Fresh Step cat litter, Hidden Valley dressings, and Brita water filtration. The Oakland, California-based company holds a market capitalization of roughly $11.5 to $11.8 billion and has historically been regarded as a defensive staple with reliable cash flows.

However, recent market activity has painted a more challenging picture. CLX shares have declined approximately 22% to 27% over the trailing 52-week period, enduring a significant drawdown from a 52-week high of $132.03 to recent trading levels near $97. The operational narrative has been shaped by a 2023 cyberattack that disrupted production and distribution, followed by a complex ERP (Enterprise Resource Planning) system implementation that created inventory distortions and slowed volume recovery. In its most recent quarterly report, CLX delivered EPS of $1.64 — beating the $1.55 estimate — while revenue of $1.67 billion came in essentially flat year over year. Management subsequently lowered its fiscal 2026 outlook, citing softer consumer demand and persistent cost pressures, and announced a CEO transition process. On the strategic front, the company's acquisition of GOJO Industries — maker of the Purell brand — for $2.25 billion represents a significant bet on expanding its Health and Wellness segment. Analyst sentiment remains cautious, with a consensus rating of Reduce and an average price target near $103. The stock's current forward P/E (price-to-earnings ratio) of approximately 15x and dividend yield above 5% have nonetheless attracted value-oriented buyers.

PG Overview and Recent Performance

PG is the undisputed heavyweight in global consumer packaged goods. Headquartered in Cincinnati, Ohio, Procter & Gamble's portfolio spans Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care segments, anchored by iconic brands such as Tide, Pampers, Gillette, Crest, and Dawn. With a market capitalization exceeding $348 billion, PG is one of the largest publicly traded companies in the world and a benchmark holding in the Consumer Staples sector.

In recent weeks, PG shares have traded near the $149–$151 range, between a 52-week low of $137.62 and a high of $167.25. The company reported fiscal third-quarter 2026 results that featured EPS of $1.59, beating the $1.56 consensus estimate, while revenue of $21.23 billion rose 7.4% year over year — though it came in slightly below analyst expectations. Organic sales, which strip out currency effects and M&A (mergers and acquisitions) impacts, grew 3%. Management maintained full-year EPS guidance of $6.83 to $7.09, even while navigating approximately $400 million in after-tax tariff-related costs and $150 million in commodity headwinds. PG's dividend pedigree is unmatched: the company recently announced its 70th consecutive annual dividend increase, having paid a dividend every year since 1890. The current yield near 2.9% and a payout ratio of roughly 63.6% underscore the safety of that income stream. With a beta of 0.39 and a P/E ratio of roughly 22x, PG offers defensive stability at a moderate valuation premium. Wall Street maintains a consensus Moderate Buy rating, with an average price target of $161.42, and JPMorgan recently reiterated its Overweight stance with a $162 target.

Trending AI Robots

For investors who prefer a data-driven approach to navigating stock selection across names like CHD, CLX, and PG, Tickeron's Trending AI Robots page offers a curated gateway into algorithmic trading. Tickeron hosts hundreds of AI-powered trading bots, each designed to trade thousands of different tickers using distinct strategies, timeframes, and risk parameters. However, only a select subset — those demonstrating the strongest alignment with prevailing market conditions — earn a place in the Trending AI Robots section. These bots employ varied trading styles, from short-term momentum-based approaches to longer-duration trend-following models, and their performance statistics are transparently displayed for evaluation. Whether an investor is seeking a bot that specializes in Consumer Staples names or one that scans for volatility-adjusted entry points across sectors, the Trending AI Robots page provides a focused starting point for exploring systematic, emotion-free trading strategies.

Head-to-Head Comparison

When evaluating CHD, CLX, and PG side by side, several contrasts emerge. PG is the clear leader in scale, geographic diversification, and dividend reliability — its $10 billion in annual dividend payments and 70-year growth streak are virtually unmatched in corporate America. Yet PG's premium P/E of approximately 22x and limited organic sales growth of around 3% mean the stock is primarily an income-and-stability proposition rather than a growth vehicle.

CHD occupies a middle ground. Its 32x P/E multiple is the highest of the three, reflecting investor confidence in the company's consistent execution, brand momentum, and acquisition strategy — recent additions such as TheraBreath, Hero, and Touchland have expanded its addressable market. The stock's beta of 0.47 and approximately 1.2% dividend yield make it a lower-volatility holding, though income-focused investors will find the yield modest relative to peers.

CLX presents the most pronounced value case — and the most visible operational risk. A 15x P/E and a dividend yield exceeding 5% are rare in the Consumer Staples sector and suggest the market has priced in considerable uncertainty. The ERP transition, CEO search, and lowered guidance add layers of execution risk. On the other hand, the GOJO acquisition could become a meaningful long-term catalyst if the integration progresses smoothly. In terms of recent momentum, CHD has clearly outperformed, PG has held relatively steady, and CLX has struggled to regain footing.

Tickeron AI Verdict

Based on observable factors — including trend consistency, earnings trajectory, institutional accumulation patterns, and relative price momentum — Tickeron's AI-driven analysis would likely favor CHD among the three in the current environment. The stock's steady climb through 2026, supported by consecutive earnings beats, reaffirmed guidance, and constructive analyst revisions, reflects a positive trend structure that algorithmic models tend to identify and follow. PG would likely register as the most statistically stable candidate, with its ultra-low beta and unmatched dividend history appealing to AI strategies optimized for risk-adjusted returns and income consistency. CLX, while offering a compelling valuation signal, would likely require a catalyst-driven or mean-reversion-oriented AI strategy given the elevated uncertainty surrounding its operational recovery. As always, the suitability of any individual stock depends on the specific objectives, time horizon, and risk parameters of the strategy being deployed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations